<?xml version='1.0' encoding='utf-8'?>
<document id="28167538"><sentence text="Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions."><entity charOffset="86-95" id="DDI-PubMed.28167538.s1.e0" text="Bosutinib" /></sentence><sentence text="Bosutinib is an orally available Src/Abl tyrosine kinase inhibitor indicated for the treatment of patients with Philadelphia chromosome-positive chronic myelogenous leukemia"><entity charOffset="0-9" id="DDI-PubMed.28167538.s2.e0" text="Bosutinib" /><entity charOffset="41-49" id="DDI-PubMed.28167538.s2.e1" text="tyrosine" /><pair ddi="false" e1="DDI-PubMed.28167538.s2.e0" e2="DDI-PubMed.28167538.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28167538.s2.e0" e2="DDI-PubMed.28167538.s2.e1" /></sentence><sentence text=" Bosutinib is predominantly metabolized by CYP3A4 as the primary clearance mechanism"><entity charOffset="1-10" id="DDI-PubMed.28167538.s3.e0" text="Bosutinib" /></sentence><sentence text=" The main objectives of this study were to 1) develop physiologically based pharmacokinetic (PBPK) models of bosutinib; 2) verify and refine the PBPK models based on clinical study results of bosutinib single-dose drug-drug interaction (DDI) with ketoconazole and rifampin, as well as single-dose drug-disease interaction (DDZI) in patients with renal and hepatic impairment; 3) apply the PBPK models to predict DDI outcomes in patients with weak and moderate CYP3A inhibitors; and 4) apply the PBPK models to predict DDZI outcomes in renally and hepatically impaired patients after multiple-dose administration"><entity charOffset="109-118" id="DDI-PubMed.28167538.s4.e0" text="bosutinib" /><entity charOffset="192-201" id="DDI-PubMed.28167538.s4.e1" text="bosutinib" /><entity charOffset="247-259" id="DDI-PubMed.28167538.s4.e2" text="ketoconazole" /><entity charOffset="264-272" id="DDI-PubMed.28167538.s4.e3" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.28167538.s4.e0" e2="DDI-PubMed.28167538.s4.e0" /><pair ddi="false" e1="DDI-PubMed.28167538.s4.e0" e2="DDI-PubMed.28167538.s4.e1" /><pair ddi="false" e1="DDI-PubMed.28167538.s4.e0" e2="DDI-PubMed.28167538.s4.e2" /><pair ddi="false" e1="DDI-PubMed.28167538.s4.e0" e2="DDI-PubMed.28167538.s4.e3" /><pair ddi="false" e1="DDI-PubMed.28167538.s4.e1" e2="DDI-PubMed.28167538.s4.e1" /><pair ddi="false" e1="DDI-PubMed.28167538.s4.e1" e2="DDI-PubMed.28167538.s4.e2" /><pair ddi="false" e1="DDI-PubMed.28167538.s4.e1" e2="DDI-PubMed.28167538.s4.e3" /><pair ddi="false" e1="DDI-PubMed.28167538.s4.e2" e2="DDI-PubMed.28167538.s4.e2" /><pair ddi="false" e1="DDI-PubMed.28167538.s4.e2" e2="DDI-PubMed.28167538.s4.e3" /></sentence><sentence text=" Results showed that the PBPK models adequately predicted bosutinib oral exposures in patients after single- and multiple-dose administrations"><entity charOffset="58-67" id="DDI-PubMed.28167538.s5.e0" text="bosutinib" /></sentence><sentence text=" The PBPK models also reasonably predicted changes in bosutinib exposures in the single-dose DDI and DDZI results, suggesting that the PBPK models were sufficiently developed and verified based on the currently available data"><entity charOffset="54-63" id="DDI-PubMed.28167538.s6.e0" text="bosutinib" /></sentence><sentence text=" Finally, the PBPK models predicted 2- to 4-fold increases in bosutinib exposures by moderate CYP3A inhibitors, as well as comparable increases in bosutinib exposures in renally and hepatically impaired patients between single- and multiple-dose administrations"><entity charOffset="62-71" id="DDI-PubMed.28167538.s7.e0" text="bosutinib" /><entity charOffset="147-156" id="DDI-PubMed.28167538.s7.e1" text="bosutinib" /><pair ddi="false" e1="DDI-PubMed.28167538.s7.e0" e2="DDI-PubMed.28167538.s7.e0" /><pair ddi="false" e1="DDI-PubMed.28167538.s7.e0" e2="DDI-PubMed.28167538.s7.e1" /></sentence><sentence text=" Given the challenges in conducting numerous DDI and DDZI studies of anticancer drugs in patients, we believe that the PBPK models verified in our study would be valuable to reasonably predict bosutinib exposures under various scenarios that have not been tested clinically"><entity charOffset="193-202" id="DDI-PubMed.28167538.s8.e0" text="bosutinib" /></sentence><sentence text="" /></document>